123207-48-7

Basic information

• Product Name: 3-(MORPHOLIN-4-YLMETHYL)ANILINE
• Synonyms: ART-CHEM-BB B016019;AKOS B016019;AKOS MSC-0189;3-(MORPHOLIN-4-YLMETHYL)ANILINE;3-MORPHOLIN-4-YLMETHYL-PHENYLAMINE;3-(4-MORPHOLINYLMETHYL)ANILINE;TIMTEC-BB SBB007086;3-(Morpholin-4-ylmethyl)aniline 95%
• CAS NO: 123207-48-7
• Molecular Formula: C₁₁H₁₆N₂O
• Molecular Weight: 192.26
• Mol File: 123207-48-7.mol
• Article Data: 11

Chemical Properties

• Melting Point: 73 °C
• Boiling Point: 0°C
• Flash Point: 0°C
• Appearance: /
• Density: 1.137 g/cm³
• Vapor Pressure: 0.000242mmHg at 25°C
• Refractive Index: 1.589
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 3-(MORPHOLIN-4-YLMETHYL)ANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(MORPHOLIN-4-YLMETHYL)ANILINE(123207-48-7)
• EPA Substance Registry System: 3-(MORPHOLIN-4-YLMETHYL)ANILINE(123207-48-7)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 34-22
• Safety Statements: 26-36/37/39
• RIDADR: 3259
• HazardClass: IRRITANT
• Hazardous Substances Data: 123207-48-7(Hazardous Substances Data)

Usage

General Description

3-(Morpholin-4-ylmethyl)aniline is a chemical compound with the molecular formula C11H16N2O. It is an aniline derivative with a morpholine substituent at the fourth carbon atom of the aromatic ring. This chemical is commonly used in the pharmaceutical and chemical industries as a building block for the synthesis of various organic compounds. It is also known for its potential medicinal properties and has been studied for its potential use in the development of pharmaceutical drugs. Additionally, it is used as a reagent in organic synthesis for the preparation of a wide range of compounds. However, due to its potential health hazards, it should be handled and used with care in laboratory and industrial settings.

InChI:InChI=1/C11H16N2O/c12-11-3-1-2-10(8-11)9-13-4-6-14-7-5-13/h1-3,8H,4-7,9,12H2

Upstream product

• 110-91-8 morpholine 
• 1709-44-0 m-aminobenzaldehyde 
• 99-61-6 3-nitro-benzaldehyde 
• 1877-77-6 3-aminobenzenemethanol 
• 3958-57-4 1-bromomethyl-3-nitrobenzene 
• 123207-57-8 3-(N-Morpholinomethyl)-1-nitrobenzene 

Downstream Products

• 954408-76-5 (2-chloro-6,7-dihydro-thieno[3,2-d]pyrimidin-4-yl)-(3-morpholin-4-ylmethyl-phenyl)-amine 
• 503183-13-9 4-[(3-(morpholin-4-ylmethyl)phenyl)hydrazono]-4H-pyrazole-3,5-diamine 
• 123207-46-5 N-[3-[(4-morpholinyl)methyl]phenyl]-2-pyridinecarbothioamide 
• 702673-32-3 N⁴-(2-(1H-imidazol-4-yl)ethyl)-5-bromo-N²-(3-(morpholinomethyl)phenyl)pyrimidine-2,4-diamine 

Relevant articles and documents

Activity of 2,6,9-trisubstituted purines as potent PDGFRα kinase inhibitors with antileukaemic activity

Receptor tyrosine kinase PDGFRα is often constitutively activated in various tumours and is regarded as a drug target. Here, we present a collection of 2,6,9-trisubstituted purines with nanomolar potency against PDGFRα and strong and selective cytotoxicity in the human eosinophilic leukaemia cell line EOL-1 that expresses the FIP1L1-PDGFRA oncogene. In treated EOL-1 cells, the example compound 14q inhibited the autophosphorylation of PDGFRα and the phosphorylation of STAT3 and ERK1/2. Interestingly, we observed pronounced and even increased effects of 14q on PDGFRα and some of its downstream signalling pathways after drug washout. In accordance with suppressed PDGFRα signalling, treated cells were arrested in the G1 phase of the cell cycle and eventually underwent apoptosis. Our results show that substituted purines can be used as specific modulators of eosinophilic leukaemia.

COMPOUNDS

A compound of formula (I): compositions and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity.

AMINE COMPOUNDS

The present invention provide a compound of the formula:wherein ring A represents an aromatic ring optionally having substituents; B, Y and Ya are the same or different and each represents a bond, etc.; R1 and R2 are the same or different and each represents a hydrogen atom, etc.; R3 represents a hydrogen atom, etc.; R4 and R5 are the same or different and each represents a hydrogen, etc.; R6 represents an indolyl group optionally having substituents; and Z and Za are the same or different and each represents a hydrogen atom, etc.; or a salt thereof or a prodrug thereof, having a somatostatin receptor binding inhibition activity and is useful for preventing and/or treating diseases associated with somatostatin.